TAZVERIK
Peaktazemetostat hydrobromide
NDAORALTABLETPriority Review
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAZVERIK (tazemetostat hydrobromide) is an oral small-molecule EZH2 inhibitor approved in June 2020 for the treatment of epithelioid sarcoma and follicular lymphoma. It works by inhibiting the epigenetic enzyme EZH2, restoring normal gene expression in tumors with EZH2 or ARID1A mutations.
Peak
At peak lifecycle stage with moderate competitive pressure (30%), the brand team is likely focused on market penetration and indication expansion rather than launch activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TAZVERIK positions careers in rare cancer and hematologic oncology, appealing to professionals interested in precision medicine and targeted therapies. Working on this product offers exposure to specialized sales channels, payer negotiations for orphan indications, and complex patient identification strategies.
Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.